Antibody libraries

US9354228B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9354228-B2
Application numberUS-201113810570-A
CountryUS
Kind codeB2
Filing dateJul 14, 2011
Priority dateJul 16, 2010
Publication dateMay 31, 2016
Grant dateMay 31, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.

First claim

Opening claim text (preview).

What is claimed is: 1. A library comprising synthetic polynucleotides that encode an antibody heavy chain or alternative scaffold containing at least about 10 4 unique antibody CDRH3 amino acid sequences, wherein each of the polynucleotides encoding the at least about 10 4 unique antibody CDRH3 amino acid sequences has an antibody CDRH3 amino acid sequence represented by the following formula: [TN1]-[DH]-[N2]- [H3-JH], wherein: TN1 is a polypeptide corresponding to any of the TN1 polypeptides of Tables 10 and 18-26, or a polypeptide produced by translation of any of the TN1 polynucleotides of Tables 25-26; DH is a polypeptide corresponding to any of the DH polypeptides of Tables 11, 17-25 and 28, or a polypeptide produced by translation of any of the DH-encoding polynucleotides of Tables 16, 25 and 27; N2 is a polypeptide corresponding to any of the N2 polypeptides of Tables 12, 18-25 and 30, or a polypeptide produced by translation of any of the N2-encoding polynucleotides of Tables 25 and 29; H3-JH is a polypeptide corresponding to any of the H3-JH polypeptides of Tables 13, 15, 18-25 and 32, or a polypeptide produced by translation of any of the H3-JH-encoding polynucleotides of Tables 14, 25 and 31; wherein the diversity of the polynucleotides encoding the at least about 10 4 unique antibody CDRH3 amino acid sequences is created by each of the polynucleotides having a CDRH3 sequence that is different from the CDRH3 sequence of every other polynucleotide; wherein the antibody heavy chain is a variable domain with framework (FRM) and complementary determining regions (CDR) comprising FRMH1-CDRH1-FRMH2-CDRH2-FRMH3-CDRH3-FRMH4; and wherein the alternative scaffold is selected from the group consisting of fibronectin, the β-sandwich, lipocalin, EETI-IFAGRP, BPTIFLAC1-D1/IT1-D2, thioredoxin, protein A, ankyrin repeats, γB-crystallin/ubiquitin, CTLD 3 and (LDLR-A module) 3 . 2. The library of claim 1 , wherein the polynucleotides encode CDRH3 polypeptides produced by the sets of TN1, DH, N2, and H3-JH polypeptides provided in any one of Tables 23-25. 3. The library of claim 1 , wherein the polynucleotides encode CDRI-13 polypeptides produced by the set of TN1 polypeptides provided in Table 26, the set of DH polypeptides provided in Table 28, the set of N2 polypeptides provided in Table 30 and the set of H3-JH polypeptides provided in Table 32. 4. The library of claim 1 wherein number of N-linked glycosylation sites, deamidation motifs, and/or Cys residues are reduced or eliminated in comparison to libraries produced by amplification of a repertoire from a biological source. 5. The library of claim 1 , further comprising a polynucleotide encoding one or more light chain variable domain polypeptides. 6. The library of claim 5 , wherein the polypeptides are expressed as full-length IgGs. 7. The polypeptide expression products of the library of claim 6 . 8. An antibody isolated from the polypeptide expression products of claim 7 . 9. A vector containing the library of claim 1 . 10. A host cell containing the vector of claim 9 . 11. The host cell of claim 10 , wherein the host cell is a yeast cell. 12. The yeast cell of claim 11 , wherein the yeast is Saccharomyces cerevisiae. 13. A kit containing the library of claim 1 .

Assignees

Inventors

Classifications

  • Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

  • from primates, e.g. man · CPC title

  • ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides · CPC title

  • In silico combinatorial chemistry · CPC title

  • C40B40/08Primary

    Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9354228B2 cover?
The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
Who is the assignee on this patent?
Vasquez Maximiliano, Sivasubramanian Arvind, Feldhaus Michael, and 1 more
What technology area does this patent fall under?
Primary CPC classification C40B40/08. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).